BRPI0515530A - compostos de piperidinilamino-tieno[2,3-d]pirimidina - Google Patents

compostos de piperidinilamino-tieno[2,3-d]pirimidina

Info

Publication number
BRPI0515530A
BRPI0515530A BRPI0515530-4A BRPI0515530A BRPI0515530A BR PI0515530 A BRPI0515530 A BR PI0515530A BR PI0515530 A BRPI0515530 A BR PI0515530A BR PI0515530 A BRPI0515530 A BR PI0515530A
Authority
BR
Brazil
Prior art keywords
compounds
piperidinylamino
novel
hypertension
piperidinylaminothieno
Prior art date
Application number
BRPI0515530-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Dale S Dhanoa
Oren Becker
Silvia Noiman
Sekar Reddy Alla
Rosa E Melendez
Anurag Sharadendu
Dongli Chen
Yael Marantz
Sharon Shacham
Alexander Heifetz
Boaz Inbal
Venkitasamy Kesavan
Shay Bar-Haim
Srinivasa Rao Cheruku
Original Assignee
Epix Delaware Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/947,995 external-priority patent/US20050222175A1/en
Application filed by Epix Delaware Inc filed Critical Epix Delaware Inc
Publication of BRPI0515530A publication Critical patent/BRPI0515530A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0515530-4A 2004-09-23 2005-09-23 compostos de piperidinilamino-tieno[2,3-d]pirimidina BRPI0515530A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/947,995 US20050222175A1 (en) 2004-03-31 2004-09-23 New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US11/075,565 US7612078B2 (en) 2003-03-31 2005-03-08 Piperidinylamino-thieno[2,3-D] pyrimidine compounds
PCT/US2005/034862 WO2006034511A1 (en) 2004-09-23 2005-09-23 Piperidinylamino-thieno[2,3-d] pyrimidine compounds

Publications (1)

Publication Number Publication Date
BRPI0515530A true BRPI0515530A (pt) 2008-07-29

Family

ID=35528225

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515530-4A BRPI0515530A (pt) 2004-09-23 2005-09-23 compostos de piperidinilamino-tieno[2,3-d]pirimidina

Country Status (21)

Country Link
US (2) US7612078B2 (OSRAM)
EP (1) EP1797099B1 (OSRAM)
JP (1) JP2008514643A (OSRAM)
KR (1) KR20070057970A (OSRAM)
CN (1) CN101048412A (OSRAM)
AR (1) AR054982A1 (OSRAM)
AT (1) ATE477257T1 (OSRAM)
AU (1) AU2005287898A1 (OSRAM)
BR (1) BRPI0515530A (OSRAM)
CA (1) CA2581175A1 (OSRAM)
DE (1) DE602005022897D1 (OSRAM)
DK (1) DK1797099T3 (OSRAM)
HR (1) HRP20100607T1 (OSRAM)
IL (1) IL182099A0 (OSRAM)
MX (1) MX2007003026A (OSRAM)
NO (1) NO20072037L (OSRAM)
NZ (1) NZ553886A (OSRAM)
PL (1) PL1797099T3 (OSRAM)
PT (1) PT1797099E (OSRAM)
TW (1) TW200628472A (OSRAM)
WO (1) WO2006034511A1 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
CA2595607C (en) * 2005-01-25 2014-07-15 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
WO2007056208A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2007056215A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc. N-aryl-thienopyrimidin-4-amines and the use thereof
WO2007056214A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
US7939661B2 (en) * 2006-09-11 2011-05-10 Hoffman-La Roche Inc. Pyridine, quinoline and pyrimidine derivatives
WO2008061968A1 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh Benzimidazolone derivates in the treatment of pulmonary arterial hypertension
WO2008061966A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh New use of flibanserin
CN101820882A (zh) * 2007-09-04 2010-09-01 Epix特拉华公司 用于治疗纤维变性的哌啶基氨基噻吩并[2,3-d]嘧啶类化合物
WO2010065743A2 (en) * 2008-12-03 2010-06-10 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
US8618116B2 (en) * 2009-08-03 2013-12-31 Daljit Singh Dhanoa Deuterium-enriched pyrimidine compounds and derivatives
JP6042331B2 (ja) 2010-07-23 2016-12-14 プレジデント アンド フェローズ オブ ハーバード カレッジ プロテアソーム活性を向上させる三環系化合物
KR101401496B1 (ko) * 2011-05-12 2014-06-11 한국화학연구원 티에노피리미딘 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 예방 또는 치료용 약학적 조성물
EP2806875B1 (en) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
CN103467596A (zh) * 2012-06-06 2013-12-25 北京大学 一个治疗肺动脉高压的新靶点
EP2968342B1 (en) * 2013-03-13 2018-10-03 The Regents of the University of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
CN104592248A (zh) * 2014-12-31 2015-05-06 芜湖杨燕制药有限公司 一种4-氯-6-取代噻吩并[2,3-d]嘧啶化合物的制备方法
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
KR102419524B1 (ko) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. 메닌-mll의 가교된 이환식 억제제 및 사용 방법
SI3512857T1 (sl) 2016-09-14 2021-07-30 Janssen Pharmaceutica Nv Spiro biciklični zaviralci interakcije menin-MLL
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
TWI753016B (zh) * 2016-09-14 2022-01-21 比利時商健生藥品公司 Menin-mll相互作用之稠合二環抑制劑
US10745409B2 (en) 2016-12-15 2020-08-18 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
CN117298275A (zh) 2017-03-24 2023-12-29 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN110075109B (zh) * 2019-03-28 2021-07-27 中国人民解放军军事科学院军事医学研究院 一种促进干细胞因子合成和分泌的化合物及其用途
IL293965A (en) 2019-12-19 2022-08-01 Janssen Pharmaceutica Nv History of Spiro straight chain transformed
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN114560843B (zh) * 2022-04-02 2023-04-18 河南维诺生物科技有限公司 一种作为荧光探针的化合物及其合成方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069412A (en) 1958-08-15 1962-12-18 Fmc Corp N-aminoazetidine and preparation thereof
CA933923A (en) 1969-12-19 1973-09-18 Eichenberger Kurt Process for the manufacture of new thiopyranes
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
DE2925175A1 (de) 1979-06-22 1981-01-08 Basf Ag Verfahren zur herstellung von isatosaeureanhydriden
IT1203323B (it) 1987-02-02 1989-02-15 Hoechst Italia Spa Additivo fotoattivatore per composizioni polimeriche costituito dal sale metallico di una cera ossidata
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
US5155115A (en) 1991-03-12 1992-10-13 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5219864A (en) 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5227387A (en) 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
DE4138820A1 (de) 1991-11-26 1993-05-27 Basf Ag Chinolin-3-carbonsaeureamide, deren herstellung und verwendung
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
DE4227747A1 (de) 1992-08-21 1994-02-24 Basf Ag Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
US5409948A (en) 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
JPH06239858A (ja) 1993-02-16 1994-08-30 Otsuka Pharmaceut Co Ltd 末梢血管拡張剤
GB9306460D0 (en) 1993-03-29 1993-05-19 Smithkline Beecham Plc Novel compounds
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
DE19636769A1 (de) 1996-09-10 1998-03-12 Basf Ag 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
DE19724980A1 (de) 1997-06-13 1998-12-17 Basf Ag 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
JPH11130777A (ja) 1997-08-13 1999-05-18 Takeda Chem Ind Ltd チエノピリジン誘導体、その中間体およびそれらの製造法
WO1999018077A1 (en) 1997-10-02 1999-04-15 Eisai Co., Ltd. Fused pyridine derivatives
WO1999043681A1 (en) 1998-02-26 1999-09-02 Neurogen Corporation 4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: gaba brain receptor ligands
DE19815026A1 (de) 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU5259100A (en) 1999-04-28 2000-11-10 Respiratorius Ab Medicament
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
AU763033B2 (en) 1999-10-01 2003-07-10 Japan Energy Corporation Novel quinazoline derivatives
EP1270568A1 (en) 2001-06-19 2003-01-02 Biofrontera Pharmaceuticals AG 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
AU2003277215A1 (en) 2002-10-01 2004-04-23 Predix Pharmaceuticals Holdings, Inc. Novel neurokinin antagonists and methods of use thereof
US7153858B2 (en) 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
WO2004089312A2 (en) 2003-03-31 2004-10-21 Predix Pharmaceuticals Holdings, Inc. New piperidinylamino-thieno[2,3-d] pyrimidine compounds
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
CN1856312A (zh) 2003-07-25 2006-11-01 弗·哈夫曼-拉罗切有限公司 治疗急性和/或慢性神经系统疾病的mGluR2拮抗剂和AChE抑制剂的组合产品
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US20060084806A1 (en) 2004-07-21 2006-04-20 Ramasubramanian Sridharan Processes for the preparation of imidazo[1,2-a] pyridine derivatives
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
CA2595607C (en) 2005-01-25 2014-07-15 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
JP2009520688A (ja) 2005-11-23 2009-05-28 エピックス デラウェア， インコーポレイテッド Ｓ１ｐ受容体調節化合物およびそれらの使用

Also Published As

Publication number Publication date
CN101048412A (zh) 2007-10-03
EP1797099B1 (en) 2010-08-11
NO20072037L (no) 2007-06-21
PL1797099T3 (pl) 2011-07-29
MX2007003026A (es) 2007-12-04
EP1797099A1 (en) 2007-06-20
AR054982A1 (es) 2007-08-01
NZ553886A (en) 2010-11-26
PT1797099E (pt) 2010-11-18
DE602005022897D1 (de) 2010-09-23
US7612078B2 (en) 2009-11-03
KR20070057970A (ko) 2007-06-07
DK1797099T3 (da) 2010-11-29
IL182099A0 (en) 2007-07-24
AU2005287898A1 (en) 2006-03-30
HRP20100607T1 (hr) 2011-03-31
US20050222176A1 (en) 2005-10-06
CA2581175A1 (en) 2006-03-30
US20100113485A1 (en) 2010-05-06
ATE477257T1 (de) 2010-08-15
JP2008514643A (ja) 2008-05-08
WO2006034511A1 (en) 2006-03-30
TW200628472A (en) 2006-08-16

Similar Documents

Publication Publication Date Title
BRPI0515530A (pt) compostos de piperidinilamino-tieno[2,3-d]pirimidina
CN100519549C (zh) 嘧啶化合物以及含有该化合物的药物组合物
TWI476192B (zh) Ｊａｋ激酶調節化合物及其使用方法
WO2004089312A3 (en) New piperidinylamino-thieno[2,3-d] pyrimidine compounds
WO2004014850A3 (en) Substituted aminopyrimidines as neurokinin antagonists
WO2004069794A3 (en) New arylpiperazinyl compounds
CL2008003056A1 (es) Compuestos derivados de 3-fenil-imidazo[1,2-a]piridinas; composicion farmaceutica; proceso para su preparacion, util como inhibidores de alk-5 o alk-4 en el tratamiento de enfermedades inflamatorias u obstructivas de las vias respiratorias, cancer, enfermedades musculares, trastornos esqueleticos
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
MA33818B1 (fr) Nouveaux antagonistes du récepteur ccr2 et leurs utilisations
BR9809648A (pt) Derivados de piperazinil-benzil-tetrazol antiinflamatórios e intermediários dos mesmos
EP2155203A4 (en) Azaindazole compounds and methods of use
NO20084375L (no) Imidazo[1,2-B]pyridaziner, deres fremstilling og deres anvendelse som GABA reseptorligander
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
BRPI0811849A8 (pt) composto, composição farmacêutica, e, métodos para preparar o composto e para tratar doenças ou condições mediadas por ccr1
Volk et al. Optimization of (arylpiperazinylbutyl) oxindoles exhibiting selective 5-HT7 receptor antagonist activity
DOP2012000032A (es) DERIVADOS DE AMIDAS ESPIROCÍCLICAS QUE POSSEN ACTIVIDAD EN LOS RECEPTORES MUSCARINICOS Y RECPETORES ß2
BRPI0415769A (pt) alcanaminas de diidrobenzofuranila e composições farmacêuticas contendo-as
Vanda et al. Imidazopyridine-Based 5-HT6 Receptor Neutral Antagonists: Impact of N 1-Benzyl and N 1-Phenylsulfonyl Fragments on Different Receptor Conformational States
SV2009002917A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos
CN102264702A (zh) 作为p2x7调节剂的二氢吡啶酮酰胺
DK2619187T3 (en) Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT 1A and 5-HT 2A receptors
KR100932623B1 (ko) 5-ｈｔ 수용기에서 활성을 갖는(3,4-다이하이드로-퀴나졸린-2-일)-(2-아릴옥시-에틸)-아민
CN103214473A (zh) 二苯并[b,f][1,4]氧杂氮杂*化合物
BRPI0514419A (pt) amidas do ácido tienopirrol carboxìlico substituìdas, amidas do ácido pirrolotiazol carboxìlico, e análogos relacionados como inibidores de caseìna cinase iépsilon, bem como composição farmacêutica e processo para a preparação dos mesmos
CN1882564A (zh) 调节类香草素－1受体(vr1)功能的吲唑－3－酮及其类似物和衍生物

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2168 DE 24/07/2012.